Compare Neurocrine Biosciences Inc (NBIX) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Vanguard S&P 500 ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.16 (market cap $14.36B), while Vanguard S&P 500 ETF trades at $713.16 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 125.3× Neurocrine Biosciences Inc's market cap, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Vanguard S&P 500 ETF for 55 Days on average.
| NBIX | VOO | |
|---|---|---|
Market Cap | $14.36B | $1.80T |
Volume | 1,237,180 | 4,722,271 |
Sector | Health | Broad Market / Factor |
52-Week High | $185.50 | $716.17 |
52-Week Low | $123.10 | $580.93 |
Typical Hold Time | 23 Days | 55 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
VOO trades at $714.42, down 0.24% with a mild bearish daily move. Technical indicators show a bullish moving average signal but neutral oscillators, with RSI at 75.83 suggesting potential overbought conditions. Recent news highlights the ETF's role in long-term wealth building amid expectations of slowing S&P 500 profit growth from 35% to 15% in 2027. Short interest increased 46.9% in September, indicating growing bearish bets.
The outlook remains cautiously optimistic given VOO's diversified exposure to the S&P 500, though elevated RSI and rising short interest signal near-term pressure. Key risks include macroeconomic headwinds from Fed rate hikes and projected earnings slowdown. The ETF continues to be favored for recession resilience and long-term dollar-cost averaging strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
